Intec Pharma Ltd. (NASDAQ:NTEC) and Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.
Table 1 showcases the top-line revenue, earnings per share and valuation of Intec Pharma Ltd. and Can-Fite BioPharma Ltd.
Table 2 hightlights the net margins, return on assets and return on equity of the two companies.
Insider Institutional Ownership
The shares of both Intec Pharma Ltd. and Can-Fite BioPharma Ltd. are owned by institutional investors at 39.64% and 23.43% respectively. About 11.81% of Intec Pharma Ltd.’s share are owned by insiders.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
For the past year Intec Pharma Ltd. has